Business Context and Reporting Period
This Form 8-K, filed on April 8, 2019, reports a material event occurring on April 5, 2019. Histogenics Corporation (the "Company") entered into an Agreement and Plan of Merger with Ocugen, Inc. ("Ocugen"). The transaction involves a reverse merger where Ocugen will become a wholly-owned subsidiary of Histogenics, which will subsequently change its name to "Ocugen, Inc." and trade on the Nasdaq Capital Market under the symbol "OCGN."
Key Financial Metrics and Transaction Terms
The filing details the structure of the merger rather than historical financial performance metrics such as revenue or cash flow. Key financial terms include:
- Ownership Structure: Former Ocugen equity holders are expected to own approximately 90% of the combined company's outstanding capital stock, while existing Histogenics stockholders are expected to own approximately 10%.
- Exchange Ratio Adjustments: The final ownership percentage may be adjusted based on Histogenics' cash at closing, proceeds from divestiture transactions (specifically the sale of assets underlying the Neocart product), and unconverted Ocugen convertible notes. Ocugen stockholders may receive up to an additional 5% of the outstanding capital stock.
- Termination Fees: If the agreement is terminated under specified circumstances, Histogenics may be required to pay Ocugen a termination fee of $600,000, or Ocugen may be required to pay Histogenics a termination fee of $700,000.
- Expense Reimbursement: In certain termination scenarios, parties may be required to reimburse the other's expenses up to a maximum of $300,000.
Material Changes and Corporate Actions
The primary material change is the proposed consolidation of the two entities. Specific corporate actions include:
- Leadership Transition: Upon closing, the Board of Directors will consist solely of members designated by Ocugen. Shankar Musunuri is expected to serve as Chairman and CEO, and Susan L. Drexler as Interim CFO.
- Divestiture: Histogenics is expected to divest assets related to its Neocart product as a condition of the merger.
- Stock Split: Histogenics will seek stockholder approval for a reverse stock split of its common stock at a ratio to be mutually agreed upon.
- Voting Agreements: Voting agreements covering approximately 68% of Ocugen's outstanding capital stock and less than 1% of Histogenics' stock have been executed to support the merger.
Guidance, Risks, and Contingencies
The filing contains extensive forward-looking statements and identifies significant risks and contingencies:
- Closing Conditions: The merger is contingent upon stockholder approval from both companies, regulatory approvals, the accuracy of representations, and the listing of shares on Nasdaq.
- Capital and Development Risks: Risks include the inability to obtain sufficient capital to advance product candidates, delays in clinical trials, and the failure to realize value from preclinical programs.
- Operational Risks: Potential unexpected costs related to the transaction and Histogenics' prior workforce reductions are noted.
- Lock-Up Agreements: Officers and directors of both companies have entered into 180-day lock-up agreements restricting the transfer of shares following the effective time.
Investor Verification Checklist
- Verify the final exchange ratio and ownership percentages once the Form S-4 proxy statement is filed.
- Confirm the status of the divestiture of Histogenics' Neocart assets and the resulting cash proceeds.
- Monitor the approval status of the merger by both Histogenics and Ocugen stockholders.
- Review the combined company's cash position at closing to assess runway for clinical development.
- Check for any competing acquisition proposals that could trigger termination fees.